Thrombolytic therapy of acute mypcardial infarction with saruplase, a single-chain urpkinase-type plasminogen activator (scu-PA) from recombinant bacteria

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 2, 1997, Pages 45-54

  Tebbe, U ^a   Gunzler W A ^b   Hopkins, G R ^b   Grymbowski, T ^b   Barth, H ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR; PROUROKINASE; SARUPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0030723376     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80070-7     Document Type: Article

References (66)

1. MacFarlane R G, Pilling F. Fibrinolytic activity in normal urine. Nature 1947; 159: 779.
2. Sobel G W, Mohler S R, Jones N W, et al. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768-769.
3. Bernik M B, Oller E P. Increase plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 1973; 52: 823-834.
4. Stump D C, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261: 1267-1273.
5. Steffens G J, Günzler W A, Ötting F, et al. The complete amino acid sequence of low molecular mass urokinase form human urine. Hoppe Seyler's Z Physiol Chem 1982; 363: 1043-1058.
6. Günzler W A, Steffens G J, Ötting F, et al. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seyler's Z Physiol Chem 1982; 363: 1155-1156.
7. Holmes W E, Pennica D, Blaber M, et al. Cloning and expression of the gene for prourokinase in Escherichia coli. Bio/Technology 1985; 3: 923-929.
8. Brigelius-Flohé R, Steffens G, Straßburger W, Flohé L. High expression vectors for the production of recombinant single-chain urinary plasminogen activator from Escherichia coli. Appl Microbiol Biotechnol 1992; 36: 640-649.
9. Pannell R, Gurewich V. Pro-urokinase - a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223.
10. Gurewich V, Pannell R, Louie S, et al. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-1739.
11. Hanbücken F W, Schneider;, Günzler W A, et al. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria. Drug Res 1987; 37: 992-997.
12. Gurewich V, Lin J N, Pannell R. The intrinsic lysis concept. In: Brakman P, Kluft C, eds. Plasminogen activation in flbrinolysis, in tissue remodelling and in development. Ann NY Acad Sci 1992; 667: 224-232.
13. Günzler W A, Beier H, Flohé L. Activity and antigen of saruplase and two-chain urokinase related plasminogen activator are stabilized by a combination of aprotinin and benzamidine in citrated plasma. Fibrinolysis 1990; 4(Suppl. 2): 145-147.
14. Koster R W, Cohen A F, Hopkins G R, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 71: 740-744.
15. PRIMI trial study group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; i: 863-868.
16. Michels R, Hoffmann H, Windeler J, et al, on behalf of the SUTAMI Investigators. A double-blind multicentre comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: Report of the SUTAMI study group. J Thrombosis and Thrombolysis 1995; 2: 117-124.
17. The Belgian saruplase alteplase trial group. Effects of alteplase and saruplase on haemostatic variables: a single-blind, randomised trial in patients with acute myocardial infarction. Cor Art Dis 1991; 2: 349-355.
18. Tebbe U, Windeler J, Boesl I, et al, on behalf of the LIMITS study group. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS Study). JACC 1995; 26: 365-373.
19. Dosne A M, Bendetowicz A V, Kher A, Samama M. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin. Thromb Res 1988; 31: 627-630.
20. Susawa T, Yui Y, Hattori R, et al. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin. Jpn Circ J 1988; 52: 72-78.
21. Lijnen H R, Collen D. Stimulation by heparin of the plasminmediated conversion of single-chain to two-chain urokinase-type plasminogen activator. Thromb Res 1986; 43: 687-690.
22. Rydzweski A, Takada Y, Takada A. Stimulation of plasmin catalyzed conversion of single-chain to two-chain urokinase-type plasminogen activator by sulfated polysaccharides. Thromb Haemost 1989; 62: 752-755.
23. Okada K, Fukao H, Tanaka H, et al. Purification and characterization of a plasma factor which cleaves single-chain form of t-PA and u-PA. Thromb Res 1990; Suppl. X: 27-43.
24. Schneider J. Interactions of saruplase with acetylcalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model. Drug Research 1990; 40: 1180-1184.
25. Van de Werf F, Vanhaeke J, de Geest H, et al. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066-1070.
26. Diefenbach C, Erbel R, Pop T, et al. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 1988; 61: 966-970.
27. Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European cooperative study group for recombinant tissue-type plasminogen activator. Lancet 1985; i: 842-847.
28. Chesebro J H, Borer J, Cohen L S, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-154.
29. Gruppo italiano per lo studio della streptochinasi nell' infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397-402.
30. ISIS-2 (Second International study of infarct survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-360.
31. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative interview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
32. Weaver W D, Cerqueira M, Hallstrom A R, et al. Prehospital-initiated vs. hospital-initiated thrombolytic therapy - the Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-1216.
33. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. NEMJ 1993; 329: 383-389.
34. The Great Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners. BMJ 1992; 305: 548-553.
35. Mueller H S, Rao A K, Forman S A. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987; 10: 479-490.
36. Sobel B E. Conundrums in coronary thrombolysis: the TIMI-II/TIMI-III flow dichotomy and the denominator problem. Cor An Dis 1996; 7: 81-82.
37. Nash J A. The open infarct-related artery: theoretical and practical considerations. Cor Art Dis 1995; 6: 739-749.
38. Kleimans N S, White H D, Ohman E M, et al, for the GUSTO investigators. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. Circulation 1994; 90: 2658-2665.
39. The SESAM investigators. Early patency and reocclusion in acute myocardial infarction. A comparison between the thrombolytic agents saruplase and alteplase. Results of the SESAM trial. JACC 1994: 345.
40. Stack R S, O'Conner C M, Mark D B, et al. Coronary perfusion during acute myocardial infarction with combined therapy of coronary angioplasty and high-dose intravenous streptokinase. Circulation 1988; 33: 151-161.
41. Simoons M L, Arnold A E R, Betriu A, et al, for the European cooperative study group for recombinant tissue-type plasminogen activator (rTPA). Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; i: 197-203.
42. Carney R J, Murphy G A, Brandt T R, et al, for the RAAMI study investigators. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. JACC 1992; 20: 17-23.
43. The TIMI study group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-627.
44. Thompson P I, Aylward P E, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991; 83: 1534-1542.
45. Neuhaus K-L, Feuerer W, Jeep-Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. JACC 1989; 14: 1566-1569.
46. Neuhaus K-L, v. Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC Patency Study (TAPS). JACC 1992; 19: 885-891.
47. Neuhaus K L, Tebbe U, Gottwick M, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Stusy (GAUS). J Am Coll Card 1988; 12: 581-587.
48. Wall T C, Phillips H R, Stack R S, et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Card 1990; 65: 124-131.
49. Brochier M L, Quilliet L, Kulbertus H, et al. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Drugs 1987; 33(Suppl. 3): 140-145.
50. Hillis W S, Hornung R S. The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction. Eur Heart J 1985; 6: 909-912.
51. Ohman E M, Califf R M, Topol E J, et al, and the TAMI study group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791.
52. Topol E J, Califf R M, George B S, et al, and the TAMI study group. Coronary arterial thrombolysis and combined infusion of recombinant tissue type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988; 77: 1100-1107.
53. The GUSTO Investigators. An international randomised trial comparing four thrombolysis strategies for acute myocardial infarction. NEJM 1993; 329: 673-682.
54. Gruppo italiano per lo studio della streptochlnasi nell'infarto miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
55. ISIS-3 (Third international study of infarct survival) collaborative group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
56. Gruppo italiano per lo studio della streptochinasi nell' infarto miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of GISSI study. Lancet 1987; ii: 871-874.
57. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; i: 545-549.
58. Tebbe U, Michels R, Adgey J, et al. Thrombolysis with saruplase is at least as effective in AMI as streptokinase: COMPASS double-blind study in 3089 patients. JACC 1996: 166A.
59. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-336.
60. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Europ Hrt J 1985; 6: 556-585.
61. Sobel B E, Nachowiak D A, Fry E T A, et al. Paradoxical attenuation of fibrinolysis attributed to 'plasminogen steal' and its implications for coronary thrombolysis. Cor Art Dis 1990; 1: 111-119.
62. Wilcox R G, von der Lippe G, Olsson C G, et al, for the Asset Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; ii: 525-530.
63. Vermeer F, Bär F, Windeler J, Schenkel W. Saruplase, a new fibrin specific thrombolytic agent; final results of the PASS study (1698 patients). Circulation 1993; 88: 292.
64. Cugno M, Cicardi M, Colucci M, et al. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost 1996; 76: 234-238.
65. Reed B R, Chen A B, Tanswell P, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost 1990; 64: 276-280.
66. Buchalter M B. Is the development of antibodies to streptokinase clinically relevant? Drugs 1994; 48: 133-136.